{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:20:32Z","timestamp":1795126832516,"version":"4.10.3"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52032008"],"award-info":[{"award-number":["52032008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Transdermal drug delivery has been regarded as an alternative to oral delivery and subcutaneous injection. However, needleless transdermal delivery of biomacromolecules remains a challenge. Herein, a transdermal delivery platform based on biocompatible fluorocarbon modified chitosan (FCS) is developed to achieve highly efficient non-invasive delivery of biomacromolecules including antibodies and antigens. The formed nanocomplexes exhibits effective transdermal penetration ability via both intercellular and transappendageal routes. Non-invasive transdermal delivery of immune checkpoint blockade antibodies induces stronger immune responses for melanoma in female mice and reduces systemic toxicity compared to intravenous injection. Moreover, transdermal delivery of a SARS-CoV-2 vaccine in female mice results in comparable humoral immunity as well as improved cellular immunity and immune memory compared to that achieved with subcutaneous vaccine injection. Additionally, FCS-based protein delivery systems demonstrate transdermal ability for rabbit and porcine skins. Thus, FCS-based transdermal delivery systems may provide a compelling opportunity to overcome the skin barrier for efficient transdermal delivery of bio-therapeutics.<\/jats:p>","DOI":"10.1038\/s41467-024-45158-6","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T16:02:14Z","timestamp":1706371334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Non-invasive transdermal delivery of biomacromolecules with fluorocarbon-modified chitosan for melanoma immunotherapy and viral vaccines"],"prefix":"10.1038","volume":"15","author":[{"given":"Wenjun","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8086-2027","authenticated-orcid":false,"given":"Ting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiutong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-5479","authenticated-orcid":false,"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-1039","authenticated-orcid":false,"given":"Zhuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"key":"45158_CR1","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/nbt.1504","volume":"26","author":"MR Prausnitz","year":"2008","unstructured":"Prausnitz, M. R. & Langer, R. Transdermal drug delivery. Nat. Biotechnol. 26, 1261\u20131268 (2008).","journal-title":"Nat. Biotechnol."},{"key":"45158_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd1304","volume":"3","author":"MR Prausnitz","year":"2004","unstructured":"Prausnitz, M. R., Mitragotri, S. & Langer, R. Current status and future potential of transdermal drug delivery. Nat. Rev. Drug Discov. 3, 115\u2013124 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"45158_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/pharmaceutics7040438","volume":"7","author":"A Alkilani","year":"2015","unstructured":"Alkilani, A., McCrudden, M. T. & Donnelly, R. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics 7, 438\u2013470 (2015).","journal-title":"Pharmaceutics"},{"key":"45158_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.addr.2003.10.023","volume":"56","author":"MR Prausnitz","year":"2004","unstructured":"Prausnitz, M. R. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56, 581\u2013587 (2004).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"45158_CR5","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1461-5347(00)00295-9","volume":"3","author":"A Naik","year":"2000","unstructured":"Naik, A., Kalia, Y. N. & Guy, R. H. Transdermal drug delivery: overcoming the skin\u2019s barrier function. Pharm. Sci. Technol. Today 3, 318\u2013326 (2000).","journal-title":"Pharm. Sci. Technol. Today"},{"key":"45158_CR6","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1073\/pnas.0501176102","volume":"102","author":"P Karande","year":"2005","unstructured":"Karande, P., Jain, A., Ergun, K., Kispersky, V. & Mitragotri, S. Design principles of chemical penetration enhancers for transdermal drug delivery. Proc. Natl Acad. Sci. USA 102, 4688\u20134693 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45158_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/1566523217666170510151540","volume":"17","author":"M Amjadi","year":"2017","unstructured":"Amjadi, M., Mostaghaci, B. & Sitti, M. Recent advances in skin penetration enhancers for transdermal gene and drug delivery. Curr. Gene Ther. 17, 139\u2013146 (2017).","journal-title":"Curr. Gene Ther."},{"key":"45158_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4014\/jmb.2003.03011","volume":"30","author":"D-G Ahn","year":"2020","unstructured":"Ahn, D.-G. et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J. Microbiol. Biotechnol. 30, 313\u2013324 (2020).","journal-title":"J. Microbiol. Biotechnol."},{"key":"45158_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.biopha.2016.08.026","volume":"83","author":"K Ita","year":"2016","unstructured":"Ita, K. Transdermal delivery of vaccines\u2014recent progress and critical issues. Biomed. Pharmacother. 83, 1080\u20131088 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"45158_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/cbdd.12008","volume":"80","author":"SA Nasrollahi","year":"2012","unstructured":"Nasrollahi, S. A., Taghibiglou, C., Azizi, E. & Farboud, E. S. Cell-penetrating peptides as a novel transdermal drug delivery system. Chem. Biol. Drug Des. 80, 639\u2013646 (2012).","journal-title":"Chem. Biol. Drug Des."},{"key":"45158_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/09687688.2010.522203","volume":"27","author":"P Desai","year":"2010","unstructured":"Desai, P., Patlolla, R. R. & Singh, M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol. Membr. Biol. 27, 247\u2013259 (2010).","journal-title":"Mol. Membr. Biol."},{"key":"45158_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41591-020-0787-6","volume":"26","author":"AR Tadros","year":"2020","unstructured":"Tadros, A. R. et al. STAR particles for enhanced topical drug and vaccine delivery. Nat. Med. 26, 341\u2013347 (2020).","journal-title":"Nat. Med."},{"key":"45158_CR13","doi-asserted-by":"publisher","first-page":"11975","DOI":"10.1073\/pnas.1118425109","volume":"109","author":"D Zheng","year":"2012","unstructured":"Zheng, D. et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc. Natl Acad. Sci. USA 109, 11975\u201311980 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45158_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nbt1193","volume":"24","author":"Y Chen","year":"2006","unstructured":"Chen, Y. et al. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat. Biotechnol. 24, 455\u2013460 (2006).","journal-title":"Nat. Biotechnol."},{"key":"45158_CR15","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3109\/10717544.2014.935532","volume":"23","author":"H Marwah","year":"2016","unstructured":"Marwah, H., Garg, T., Goyal, A. K. & Rath, G. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv. 23, 564\u2013578 (2016).","journal-title":"Drug Deliv."},{"key":"45158_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1567201043480045","volume":"1","author":"S Cross","year":"2004","unstructured":"Cross, S. & Roberts, M. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr. Drug Deliv. 1, 81\u201392 (2004).","journal-title":"Curr. Drug Deliv."},{"key":"45158_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2174\/156720106777731091","volume":"3","author":"A Nanda","year":"2006","unstructured":"Nanda, A., Nanda, S. & Khan Ghilzai, N. Current developments using emerging transdermal technologies in physical enhancement methods. Curr. Drug Deliv. 3, 233\u2013242 (2006).","journal-title":"Curr. Drug Deliv."},{"key":"45158_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16505-0","volume":"11","author":"TRF Smith","year":"2020","unstructured":"Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).","journal-title":"Nat. Commun."},{"key":"45158_CR19","doi-asserted-by":"publisher","first-page":"e2110817118","DOI":"10.1073\/pnas.2110817118","volume":"118","author":"D Xia","year":"2021","unstructured":"Xia, D. et al. An ultra-low-cost electroporator with microneedle electrodes (ePatch) for SARS-CoV-2 vaccination. Proc. Natl Acad. Sci. USA 118, e2110817118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45158_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41551-020-00650-4","volume":"5","author":"KTM Tran","year":"2020","unstructured":"Tran, K. T. M. et al. Transdermal microneedles for the programmable burst release of multiple vaccine payloads. Nat. Biomed. Eng. 5, 998\u20131007 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"45158_CR21","doi-asserted-by":"publisher","first-page":"118643","DOI":"10.1016\/j.molliq.2022.118643","volume":"351","author":"B Lu","year":"2022","unstructured":"Lu, B. et al. Ionic liquid transdermal delivery system: progress, prospects, and challenges. J. Mol. Liq. 351, 118643 (2022).","journal-title":"J. Mol. Liq."},{"key":"45158_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.actbio.2021.11.033","volume":"140","author":"X Song","year":"2022","unstructured":"Song, X. et al. Transcutaneous tumor vaccination combined with anti-programmed death-1 monoclonal antibody treatment produces a synergistic antitumor effect. Acta Biomater. 140, 247\u2013260 (2022).","journal-title":"Acta Biomater."},{"key":"45158_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jconrel.2020.07.047","volume":"327","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Galactosylated chitosan-modified ethosomes combined with silk fibroin nanofibers is useful in transcutaneous immunization. J. Controlled Release 327, 88\u201399 (2020).","journal-title":"J. Controlled Release"},{"key":"45158_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cis.2018.11.008","volume":"263","author":"Z Shariatinia","year":"2019","unstructured":"Shariatinia, Z. Pharmaceutical applications of chitosan. Adv. Colloid Interface Sci. 263, 131\u2013194 (2019).","journal-title":"Adv. Colloid Interface Sci."},{"key":"45158_CR25","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1021\/acsnano.9b06689","volume":"14","author":"G Li","year":"2020","unstructured":"Li, G. et al. Fluorinated chitosan to enhance transmucosal delivery of sonosensitizer-conjugated catalase for sonodynamic bladder cancer treatment post-intravesical instillation. ACS Nano 14, 1586\u20131599 (2020).","journal-title":"ACS Nano"},{"key":"45158_CR26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.cclet.2018.10.037","volume":"29","author":"X Zhou","year":"2018","unstructured":"Zhou, X. et al. Nano-formulations for transdermal drug delivery: a review. Chin. Chem. Lett. 29, 1713\u20131724 (2018).","journal-title":"Chin. Chem. Lett."},{"key":"45158_CR27","first-page":"100027","volume":"1","author":"X-Q Niu","year":"2019","unstructured":"Niu, X.-Q. et al. Mechanism investigation of ethosomes transdermal permeation. Int J. Pharm. X 1, 100027 (2019).","journal-title":"Int J. Pharm. X"},{"key":"45158_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0168-3659(94)90078-7","volume":"29","author":"HL Lue\u00dfen","year":"1994","unstructured":"Lue\u00dfen, H. L. et al. Bioadhesive polymers for the peroral delivery of peptide drugs. J. Controlled Release 29, 329\u2013338 (1994).","journal-title":"J. Controlled Release"},{"key":"45158_CR29","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1023\/A:1018901302450","volume":"11","author":"L Illum","year":"1994","unstructured":"Illum, L., Farraj, N. F. & Davis, S. S. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11, 1186\u20131189 (1994).","journal-title":"Pharm. Res."},{"key":"45158_CR30","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1021\/acs.molpharmaceut.9b00733","volume":"16","author":"IE Antonescu","year":"2019","unstructured":"Antonescu, I. E. et al. The permeation of acamprosate is predominantly caused by paracellular diffusion across CaCo-2 cell monolayers: a paracellular modeling approach. Mol. Pharm. 16, 4636\u20134650 (2019).","journal-title":"Mol. Pharm."},{"key":"45158_CR31","doi-asserted-by":"publisher","first-page":"e0190319","DOI":"10.1371\/journal.pone.0190319","volume":"12","author":"K Bittermann","year":"2017","unstructured":"Bittermann, K. & Goss, K.-U. Predicting apparent passive permeability of CaCo-2 and MDCK cell-monolayers: a mechanistic model. PLoS ONE 12, e0190319 (2017).","journal-title":"PLoS ONE"},{"key":"45158_CR32","doi-asserted-by":"publisher","first-page":"e132055","DOI":"10.1172\/jci.insight.132055","volume":"5","author":"S Ahmadi","year":"2020","unstructured":"Ahmadi, S. et al. A human-origin probiotic cocktail ameliorates aging-related leaky gut and inflammation via modulating the microbiota\/taurine\/tight junction axis. JCI Insight 5, e132055 (2020).","journal-title":"JCI Insight"},{"key":"45158_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/acs.chemrev.9b00264","volume":"120","author":"J Robert-Paganin","year":"2020","unstructured":"Robert-Paganin, J., Pylypenko, O., Kikuti, C., Sweeney, H. L. & Houdusse, A. Force generation by myosin motors: a structural perspective. Chem. Rev. 120, 5\u201335 (2020).","journal-title":"Chem. Rev."},{"key":"45158_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/17425247.2020.1713087","volume":"17","author":"A Kov\u00e1\u010dik","year":"2020","unstructured":"Kov\u00e1\u010dik, A., Kope\u010dn\u00e1, M. & V\u00e1vrov\u00e1, K. Permeation enhancers in transdermal drug delivery: benefits and limitations. Expert Opin. Drug Deliv. 17, 145\u2013155 (2020).","journal-title":"Expert Opin. Drug Deliv."},{"key":"45158_CR35","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1021\/acsnano.7b06969","volume":"12","author":"K Fan","year":"2018","unstructured":"Fan, K. et al. Ferritin nanocarrier traverses the blood brain barrier and kills glioma. ACS Nano 12, 4105\u20134115 (2018).","journal-title":"ACS Nano"},{"key":"45158_CR36","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1515\/ntrev-2019-0051","volume":"8","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. A brief review for fluorinated carbon: synthesis, properties and applications. Nanotechnol. Rev. 8, 573\u2013586 (2019).","journal-title":"Nanotechnol. Rev."},{"key":"45158_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jfluchem.2006.11.014","volume":"128","author":"Y-S Lee","year":"2007","unstructured":"Lee, Y.-S. Syntheses and properties of fluorinated carbon materials. J. Fluor Chem. 128, 392\u2013403 (2007).","journal-title":"J. Fluor Chem."},{"key":"45158_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","volume":"355","author":"AJ Miller","year":"2006","unstructured":"Miller, A. J. & Mihm, M. C. Melanoma. N. Engl. J. Med. 355, 51\u201365 (2006).","journal-title":"N. Engl. J. Med."},{"key":"45158_CR39","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","volume":"43","author":"C Franklin","year":"2017","unstructured":"Franklin, C., Livingstone, E., Roesch, A., Schilling, B. & Schadendorf, D. Immunotherapy in melanoma: recent advances and future directions. Eur. J. Surg. Oncol. 43, 604\u2013611 (2017).","journal-title":"Eur. J. Surg. Oncol."},{"key":"45158_CR40","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1517\/14740338.2015.1021774","volume":"14","author":"J Martin-Liberal","year":"2015","unstructured":"Martin-Liberal, J., Kordbacheh, T. & Larkin, J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin. Drug Saf. 14, 957\u2013964 (2015).","journal-title":"Expert Opin. Drug Saf."},{"key":"45158_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao, X. et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27, 635\u2013646 (2007).","journal-title":"Immunity"},{"key":"45158_CR42","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133.e17 (2017).","journal-title":"Cell"},{"key":"45158_CR43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 8, 86 (2018).","journal-title":"Front Oncol."},{"key":"45158_CR44","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer, F. et al. The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell 38, 685\u2013700.e8 (2020).","journal-title":"Cancer Cell"},{"key":"45158_CR45","doi-asserted-by":"publisher","first-page":"622509","DOI":"10.3389\/fimmu.2020.622509","volume":"11","author":"W Jiang","year":"2021","unstructured":"Jiang, W. et al. Exhausted CD8+T cells in the tumor immune microenvironment: new pathways to therapy. Front Immunol. 11, 622509 (2021).","journal-title":"Front Immunol."},{"key":"45158_CR46","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fimmu.2020.00266","volume":"11","author":"J Pielenhofer","year":"2020","unstructured":"Pielenhofer, J., Sohl, J., Windbergs, M., Langguth, P. & Radsak, M. P. Current progress in particle-based systems for transdermal vaccine delivery. Front. Immunol. 11, 266 (2020).","journal-title":"Front. Immunol."},{"key":"45158_CR47","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"45158_CR48","doi-asserted-by":"publisher","first-page":"9627","DOI":"10.1021\/acsnano.0c10180","volume":"15","author":"U Elia","year":"2021","unstructured":"Elia, U. et al. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. ACS Nano 15, 9627\u20139637 (2021).","journal-title":"ACS Nano"},{"key":"45158_CR49","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"N-N Zhang","year":"2020","unstructured":"Zhang, N.-N. et al. A thermostable mRNA vaccine against COVID-19. Cell 182, 1271\u20131283.e16 (2020).","journal-title":"Cell"},{"key":"45158_CR50","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/vaccines11030682","volume":"11","author":"C Chakraborty","year":"2023","unstructured":"Chakraborty, C., Bhattacharya, M. & Dhama, K. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic. Vaccines 11, 682 (2023).","journal-title":"Vaccines"},{"key":"45158_CR51","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.4161\/cbt.10.12.13450","volume":"10","author":"Y Cheng","year":"2010","unstructured":"Cheng, Y. & Xu, F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol. Ther. 10, 1219\u20131223 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"45158_CR52","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","volume":"183","author":"C Rydyznski Moderbacher","year":"2020","unstructured":"Rydyznski Moderbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996\u20131012.e19 (2020).","journal-title":"Cell"},{"key":"45158_CR53","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12072-017-9805-2","volume":"11","author":"J Shi","year":"2017","unstructured":"Shi, J., Li, Y., Chang, W., Zhang, X. & Wang, F.-S. Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatol. Int 11, 374\u2013383 (2017).","journal-title":"Hepatol. Int"},{"key":"45158_CR54","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/v9060148","volume":"9","author":"M Rahe","year":"2017","unstructured":"Rahe, M. & Murtaugh, M. Mechanisms of adaptive immunity to porcine reproductive and respiratory syndrome virus. Viruses 9, 148 (2017).","journal-title":"Viruses"},{"key":"45158_CR55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41578-019-0110-7","volume":"4","author":"A Schudel","year":"2019","unstructured":"Schudel, A., Francis, D. M. & Thomas, S. N. Material design for lymph node drug delivery. Nat. Rev. Mater. 4, 415\u2013428 (2019).","journal-title":"Nat. Rev. Mater."},{"key":"45158_CR56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/ITT.S141577","volume":"6","author":"M Davies","year":"2017","unstructured":"Davies, M. & Duffield, E. A. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther. 6, 51\u201371 (2017).","journal-title":"Immunotargets Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45158-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45158-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45158-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T16:02:29Z","timestamp":1706371349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45158-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45158"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45158-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]},"assertion":[{"value":"5 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"820"}}